Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 38, Issue 6, 2009, Pages 439-444

  Klimiuk, P A ^a   Sierakowski, S ^a   Domyslawska, I ^a   Chwiecko, J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; INTERCELLULAR ADHESION MOLECULE 1; MEPREDNISONE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JOINT SWELLING; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 70450202407     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903079321     Document Type: Article

References (38)

1. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders Company, 1997:851-897
2. Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997;/151:/1311-9.
3. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: Advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000;/43:/2619-33.
4. Blann AD, Herrick A, Jayson MIV. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995;/34:/814-9.
5. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum 1996;/25:/215-34.
6. Mojcik CF, Shevach EM. Adhesion molecules: A rheumatologic perspective. Arthritis Rheum 1997;/40:/991-1004.
7. Tokuhira M, Hosaka S, Volin MV, Haines GK 3rd, Katschke KJ Jr, Kim S, et al. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 2000;/43:/1122-33.
8. Brenchley PEC. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 2001;/60:/iii71-4.
9. Paleolog EM. Angiogenesis: A critical process in the pathogenesis of RA-a role for VEGF? Br J Rheumatol 1996;/35:/917-20.
10. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;/376:/517-9.
11. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002;/61:/804-9.
12. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;/340:/253-9.
13. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;/130:/478-86.
14. Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al; Add Enbrel or Replace Methotrexate study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. Ann Rheum Dis 2006;/ 65:/1478-83.
15. Aggarwal A, Panda S, Misra R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: A time kinetic study. Ann Rheum Dis 2004;/63 :/891-2.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;/31:/315-24.
17. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;/140:/659-62.
18. Prevoo ML, Van 't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;/38:/44-8.
19. Schmitt-Sody M, Metz P, Klose A, Gottschalk O, Zysk S, Hausdorf J, et al. In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: The role of P-selectin. Scand J Rheumatol 2007;/36:/311-19.
20. Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, et al. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and disease human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994;/37:/221-31.
21. Tak PP, Thurkow EW, Daha MR, Kluin PM, Smeets TJ, Meinders AE, et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin Immunol Immunopathol 1995;/77:/236-42.
22. Kuryliszyn-Moskal A, Bernacka K, Klimiuk PA. Circulating intercellular adhesion molecule 1 in rheumatoid arthritis-relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin Rheumatol 1996;/15:/367-73.
23. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997;/ 36:/164-9.
24. Nassonov EL, Samsonov MY, Chichasova NV, Nikiphorova EL, Tilz GP, Demel U, et al. Soluble adhesion molecules in rheumatoid arthritis. Rheumatology (Oxford) 2000;/39:/808-10.
25. Klimiuk PA, Fiedorczyk M, Sierakowski S, Chwiecko J. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol 2007;/36:/345-50.
26. Carter RA, Wicks IP. Vascular cell adhesion molecule 1 (CD106). A multifaceted regulator of joint inflammation. Arthritis Rheum 2001;/44:/985-94.
27. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;/41:/1258-65.
28. Klimiuk PA, Sierakowski S, Domysl awska I, Fiedorczyk M, Chwiecko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 2004;/52:/36-42.
29. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;/24:/373-9.
30. Levälampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007;/36:/189-93.
31. To SST, Newman PM, Hyland VJ, Robinson BG, Schrieber L. Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. Arthritis Rheum 1996;/39:/467-77.
32. Ferrara N. Leukocyte adhesion. Missing link in angiogenesis. Nature 1995;/376:/467.
33. Maini RN, Taylor PC, Paleolog E, Charles P, Ballara S, Brennan FM, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999;/58(Suppl 1):/I56-60.
34. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;/41:/1258-65.
35. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998;/ 27:/377-80. (Pubitemid 28480230)
36. Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001;/19:/321-4.
37. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 1993;/36:/1098-102.
38. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis. Arthritis Rheum 1996;/39:/1082-91.